UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November, 2026
Commission File Number: 001-42155
Ping An Biomedical Co., Ltd.
(Registrant’s Name)
22/F, China United Plaza, 1002-1008, Tai Nan
West Street,
Cheung Sha Wan, Kowloon, Hong Kong
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Notice of Regained Compliance with Nasdaq Listing
Rules
As previously disclosed, on November 24, 2025,
Ping An Biomedical Co., Ltd. (the “Company”) received a letter from the Listing Qualifications staff of The Nasdaq Stock
Market (“Nasdaq”) notifying the Company that the bid price of the Company had closed at less than $1 per share over the previous
30 consecutive business days, and, as a result did not comply with Listing Rule 5550(a)(2).
Also as previously disclosed, the Company received
a letter from Nasdaq on May 26, 2026, noting that while the Company’s listed security has not regained compliance with the minimum
$1 bid price per share requirement, Staff has determined that the Company is eligible for an additional 180 calendar day period, or until
November 23, 2026, to regain compliance. Nasdaq’s determination is based on the Company meeting the continued listing requirement
for market value of publicly held shares and all other applicable requirements for initial listing on the Capital Market with the exception
of the bid price requirement, and the Company’s written notice of its intention to cure the deficiency during the second compliance
period by effecting a reverse stock split, if necessary. If at any time during this additional time period the closing bid price of the
Company’s security is at least $1 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation
of compliance and the matter will be closed.
On November 16, 2026, the Company received formal
notification from Nasdaq, that the Company has regained compliance with the Nasdaq Minimum Bid Price Requirement. Nasdaq made this determination
of compliance after the closing bid price of the Company’s ordinary shares was at $1.00 per share or greater for the last 10 consecutive
business days from November 2, 2026 to November 13, 2026. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2)
and Nasdaq considers the prior bid price deficiency matter now closed.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
PING AN BIOMEDICAL CO., LTD. |
| |
|
|
| Date: November 17, 2026 |
By: |
/s/
Pijun Liu |
| |
Name: |
Pijun Liu |
| |
Title: |
Chairperson of the Board
of Directors |